Thanks for the detailed post sox. It's good to be

Thanks for the detailed post sox. It's good to be reminded of a little bit of the history behind P and good for those who are unfamiliar with P to get some DD.
My continued take away from your post about P is the confidence and humility CTIX management has. They are humble enough to admit that P is one of the most risky drugs they have in development, but confident enough it their research and pre-clinical work that they are planning for success by ordering all of the drug needed for the phase 3 trial.

Leo's quote from the SA article: "If the results of the initial trial are unfavorable, we of course would have some decisions to make in that regard as well. Obviously, we have a high degree of expectations as we will have produced all of the drug needed for a phase II/III trial, but we are aware of all possibilities. It is simply a bridge that we will cross when we get there."

This is confidence is not limited to P either as those you have followed CTIX for the last year know. Brilacidin was meticulously manufactured to market grade for the ABSSSI trials so that there will not need to be downstream costs and delays for reformulation upon FDA approval. Also it was clearly stated that the B-Ulcerative Proctitis trials would not move forward if the B-OM trial was not showing anti-inflammatory properties. Even though we have not had an interim B-OM update CTIX announced early this year they are moving forward with B-UP.

For a company operating on so many fronts and managing a limited budget this display of confidence through management choices is very telling. It tells me that while they are humble enough to manage to their resources (i.e. the delay of the P trial in 2014 in favor of the B-ABSSSI trial), they are confident that spending the extra time and resources to plan for success is going to pay off in the end.